medigraphic.com
ISSN 1025-0255 (Electronic)

2022, Number 1

<< Back Next >>

AMC 2022; 26 (1)

Giant ovarian mucinous borderline cystoadenoma, in a posmenopausic patient

Martínez-Rosales O, Solarana-Ortiz JA, de los Ángeles-Ritchie, Aniusky

Language: Spanish
References: 12
Page:
PDF size: 549.58 Kb.


ABSTRACT

Introduction: Ovarian tumors are not as frequent as those of the uterus and breast. They constitute the third group of benign and malignant tumors in women. Border cystadenoma has clinicopathologic intermediate features between those of benign and malignant tumors.
Objective: To describe the successful therapeutic management of a case of a postmenopausal woman with borderline mucus cystadenoma of ovary.
Case report: A hypertensive and diabetic patient, operated in the Lucia Iñiguez Landín Clinical Surgical Hospital in Holguin province, 54-year-old postmenopausal, with a giant tumor of the left ovary and satisfactory clinical-surgical evolution.
Conclusions: Border mucinous cystadenoma is usually limited to the ovary at the time of diagnosis, without capsular or peritoneal invasion. The risk of malignant degeneration is highly variable and is related to age. For its treatment, oophorectomy, omentectomy and biopsy of the contralateral ovary, retroperitoneal nodes, visible peritoneal nodules and cytology of peritoneal fluid are recommended.


REFERENCES

  1. López Carpintero N, Salazar Arquero FJ, Ibáñez Santamaría A, Fuente Valero J de la, Aramendi Sánchez T, Hernández Aguado JJ. Tumor ovárico benigno proliferante mucinoso de tipo endocervical con hiperplasia microglandular. Ginecol obstet Méx [Internet]. 2018 [citado 08 Abr 2021];86(4):281-88. Disponible en: Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0300-90412018000400281&lang=pt 1.

  2. Heller D, Nguyen L, Goldsmith LT. Association of cervical microglandular hyperplasia with exogenous progestin exposure. J Low Genit Tract Dis [Internet]. 2016 Abr [citado 20 Mar 2021];20(2):162-164. Disponible en: Disponible en: https://scholarship.libraries.rutgers.edu/discovery/fulldisplay/alma991031550137804646/01RUT_INST:ResearchRepository 2.

  3. Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO Classification of Tumours of Female Reproductive Organs [Internet]. Lyon: International Agency for Researchon Cancer;2014 [citado 20 Mar 2021]. Disponible en: Disponible en: https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/WHO-Classification-Of-Tumours-Of-Female-Reproductive-Organs-2014 3.

  4. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. International Journal of Women's Health [Internet]. 2019 Abr [citado 12 Ene 2021];11:287-299. Disponible en: Disponible en: https://www.researchgate.net/publication/332747210_Ovarian_cancer_in_the_world_Epidemiology_and_risk_factors 4.

  5. Taylor J, McCluggage WG. Ovarian seromucinous carcinoma: report of a series of a newly categorized and uncommon neoplasm. Am J Surg Pathol [Internet]. 2015 Jul [citado 12 Ene 2021];39(7):983-92. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/25723110/ 5.

  6. Forteza Sáez M, Pérez Trejo M, García Socarrás D, Almeida Arias DA. Cistoadenomamucinoso gigante de ovario de bajo grado de malignidad. Rev Cuba Obstetr Ginecol [Internet]. 2017 [citado 08 Abr 2021];43(3):119-124. Disponible en: Disponible en: http://revginecobstetricia.sld.cu/index.php/gin/article/view/240 6.

  7. Cortés Morera A, Ibáñez Morera M, Hernández Lara A, Garcí a Carranza MA. Cáncer de Ovario. Tamizaje y diagnóstico imagenológico. Rev Med leg Costa Rica [Internet]. Mar 2020 [citado 08 Abr 2021];37(1). Disponible en: Disponible en: https://www.scielo.sa.cr/scielo.php?script=sci_arttext&pid=S1409-00152020000100054 7.

  8. Javadi S,Ganeshan D,Qayyum A, Iyer R, Bhosale P. Ovarian Cancer, the Revised FIGO Staging System, and the Role of Imaging. AJR Am J Roentgenol [Internet]. 2016 Jun [citado 04 Abr 2021];206(6):1351-60. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/27042752/. 8.

  9. Carlson KJ, Skates SJ, Singer DE. Screening for ovarian cancer. Ann Intern Med [Internet]. 1994 Jul [citado 03 Mar 2021];121(2):124-32. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/8017726/ 9.

  10. Meissnitzer M, Cunha T. Update on Imaging of Ovarian Cancer. Current Radiology Reports [Internet]. 2016 [citado 04 Abr 2021];4(6):1-11. Disponible en: Disponible en: https://www.researchgate.net/publication/300078957_Update_on_Imaging_of_Ovarian_Cancer 10.

  11. Nyangoh Timoh K, Bendifallah S, Dion L, Ouldamer L, Leveque J. Tumores de ovario límite: Directrices de la CNGOF para la práctica clínica-valor de los marcadores tumorales. Gynecol Obstet Fertil Senol. 2020 Mar;48(3):277-86. Doi: 10.1016/j.gofs.2020.01.015.

  12. Canlorbe G, Lecointre L, Chauvet P, Azais H, Fauvet R, Uzan C. Tumores ováricos limítrofes: Directrices de la CNGOF para la práctica clínica: Manejo terapéutico de las etapas iniciales. Gynecol Obstet Fertil Senol . 2020 Mar;48(3):287-303. Doi: 10.1016/j.gofs.2020.01.016




2020     |     www.medigraphic.com